Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 35 Carcinoma, Non-Small-Cell Lung 32 Colorectal Neoplasms 19 Esophageal Squamous Cell Carcinoma 18 Stomach Neoplasms 17 Squamous Cell Carcinoma of Head and Neck 16 Rectal Neoplasms 11 Cholangiocarcinoma 11 Head and Neck Neoplasms 10 Small Cell Lung Carcinoma 9 Lung Neoplasms 9 Esophageal Neoplasms 9 Triple Negative Breast Neoplasms 8 Uterine Cervical Neoplasms 7 Nasopharyngeal Carcinoma 7 Urinary Bladder Neoplasms 6 Recurrence 6 Pancreatic Neoplasms 6 Neoplasms 6 Colonic Neoplasms 6 Melanoma 5 Hodgkin Disease 5 Biliary Tract Neoplasms 4 Adenocarcinoma of Lung 4 Sarcoma 3 Non-Muscle Invasive Bladder Neoplasms 3 Neoplasm Metastasis 3 NSCLC 3 Locally Advanced Rectal Cancer 3 Liver Neoplasms 3

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × tislelizumab × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡